|
Promoter status
|
HRM
|
MSP
|
PSQ
|
|---|
|
Methylated MGMT promoter
|
|
Progression-free survival
|
|
Median duration (months)
|
6.0 (3.64–8.36)
|
4.4 (3.09–5.72)
|
4.6 (2.88–6.32)
|
|
Rate at 6 months (%)
|
51.9
|
40.0
|
46.7
|
|
Overall survival
|
|
Median duration (months)
|
14.0 (6.50–21.50)
|
11.0 (8.19–13.81)
|
11.0 (0.27–21.74)
|
|
Rate at 18 months (%)
|
48.1
|
40.0
|
46.7
|
|
Unmethylated MGMT promoter
|
|
Progression-free survival
|
|
Median duration (months)
|
4.0 (3.80–4.20)
|
4.2 (3.67–4.73)
|
4.0 (3.67–4.33)
|
|
Rate at 6 months (%)
|
31.6
|
40.0
|
34.3
|
|
Overall survival
|
|
Median duration (months)
|
10.0 (5.03–14.97)
|
12.0 (7.36–16.64)
|
11.0 (7.62–14.38)
|
|
Rate at 18 months (%)
|
23.7
|
31.1
|
22.9
|
- Numbers in parentheses are 95 % confidence intervals
